VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.
Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).
VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.
What if you could identify high risk patients at the earliest stage of their cardiovascular disease?
VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.
Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.
The POC testing market is set to reach $49 billion by 2018.
The unique invention, which builds on a research line that was started as early as in 1982 by VitaK’s CSO, Associate Professor Dr. Cees Vermeer, was initiated with the discovery of vitamin K-dependent enzyme systems in the kidney. The complete research has been laid down in 32 papers in the international scientific literature. From these studies it turned out that low vitamin K intake and poor blood vitamin K status have a negative effect on kidney function. In collaboration with Groningen University it was discovered that this also holds true for the function of the transplanted kidney and for survival of the kidney transplant recipient.
TransCare is capable of quickly and accurately measuring the PIVKA and thus of monitoring the patient’s vitamin K status; it also visualizes how by increased dietary vitamin K intake the PIVKA (and hence the risk factor) is decreased or even annihilated.TransCare is based on the laminar flow technique and measures the occurrence of protein induced by vitamin K absence (PIVKA) in the blood stream. It is used to monitor the risk of allograft rejection after organ transplantation.
The PIVKA that is quantified was demonstrated to be strongly increased in subjects with high risk of allograft rejection and mortality. TransCare is based on patent applications WO 2013/182578 A1 and WO 2013/182579 A1. “Our studies have demonstrated that both the risk of allograft rejection and the life expectancy of the kidney transplant recipient depend on the vitamin K status of the patient. Patients with a relatively poor vitamin K status had a three-fold higher 10-year mortality risk than those with an adequate vitamin K status (45% vs. 15%).The TransCare system provides the possibility of risk reduction by relatively small adaptations in the diet, and to monitor the result thereof on a weekly basis”, says the inventor of this new technology, Associate Professor Dr. Cees Vermeer.
6229 EV Maastricht
T: +31 (0)43 388 5926
6229 EV Maastricht